Annexon, Inc. Insider Trading
ANNX
Insiders bought $3.86M and sold 313K on the open market.
None of the selling was scheduled in advance under a 10b5-1 plan.
Get an email when ANNX's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Nov 19 | William H. Carson Director | Bought | 34,000 | $3.58 | 122K | 43% | Form 4 |
| Sep 24 | Douglas Love President and CEO | Bought | 26,065 | $3.83 | 100K | 7.2% | Form 4 |
| May 28 | Muneer A Satter Director | Bought | 613,497 | $5.41 | $3.32M | 6.3% | Form 4 |
| May 11 | William H. Carson Director | Bought | 8,000 | $5.78 | 46K | 11% | Form 4 |
| Apr 10 | William H. Carson Director | Bought | 8,000 | $6.20 | 50K | 13% | Form 4 |
| Mar 10 | William H. Carson Director | Bought | 8,000 | $5.67 | 45K | 15% | Form 4 |
| Mar 2 | Dean Richard Artis EVP & Chief Scientific Officer | SoldNo plan | 5,894 | $5.43 | 32K | 3.2% | Form 4 |
| Mar 2 | Ted Yednock EVP & Chief Innovation Officer | SoldNo plan | 5,566 | $5.42 | 30K | 3.5% | Form 4 |
| Mar 2 | Michael Overdorf EVP & Chief Business Officer | SoldNo plan | 4,339 | $5.42 | 24K | 2.3% | Form 4 |
| Mar 2 | Jamie Dananberg Chief Medical Officer | SoldNo plan | 5,820 | $5.43 | 32K | 4.5% | Form 4 |
| Mar 2 | Jennifer Lew EVP & Chief Financial Officer | SoldNo plan | 5,565 | $5.42 | 30K | 3.2% | Form 4 |
| Feb 18 | Dean Richard Artis EVP & Chief Scientific Officer | SoldNo plan | 5,290 | $5.10 | 27K | 4.1% | Form 4 |
| Feb 18 | Ted Yednock EVP & Chief Innovation Officer | SoldNo plan | 7,857 | $5.11 | 40K | 7.5% | Form 4 |
| Feb 18 | Michael Overdorf EVP & Chief Business Officer | SoldNo plan | 6,225 | $5.10 | 32K | 4.8% | Form 4 |
| Feb 18 | Jamie Dananberg Chief Medical Officer | SoldNo plan | 5,290 | $5.10 | 27K | 6.7% | Form 4 |
| Feb 18 | Jennifer Lew EVP & Chief Financial Officer | SoldNo plan | 7,851 | $5.11 | 40K | 6.5% | Form 4 |
| Dec 30, 2025 | William H. Carson Director | Bought | 4,115 | $5.02 | 21K | 8.2% | Form 4 |
| Dec 1, 2025 | William H. Carson Director | Bought | 4,115 | $4.47 | 18K | 8.9% | Form 4 |
| Dec 1, 2025 | Jung Choi Director | Bought | 33,000 | $4.19 | 138K | New | Form 4 |
| Nov 20, 2025 – Nov 21, 2025 | Muneer A Satter Director | Bought 2 parts | 822,613 | $4.38 average | $3.6M | 9.2% | Form 4 |
| Nov 17, 2025 – Nov 19, 2025 | Muneer A Satter Director | Bought 3 parts | 1,500,000 | $3.37 average | $5.05M | 20% | Form 4 |
| Oct 30, 2025 | William H. Carson Director | Bought | 4,115 | $3.17 | 13K | 9.8% | Form 4 |
| Sep 30, 2025 | William H. Carson Director | Bought | 4,115 | $3.05 | 13K | 11% | Form 4 |
| Sep 2, 2025 | William H. Carson Director | Bought | 4,115 | $2.09 | 9K | 12% | Form 4 |
| Jul 30, 2025 | William H. Carson Director | Bought | 4,115 | $2.43 | 10K | 14% | Form 4 |
| Jul 14, 2025 | Ted Yednock EVP & Chief Innovation Officer | SoldNo plan | 1,116 | $2.58 | 3K | 1.1% | Form 4 |
| Jul 14, 2025 | Jennifer Lew EVP & Chief Financial Officer | SoldNo plan | 1,117 | $2.58 | 3K | 0.9% | Form 4 |
| Jul 14, 2025 | Michael Overdorf EVP & Chief Business Officer | SoldNo plan | 853 | $2.61 | 2K | 0.6% | Form 4 |
| Jun 30, 2025 | William H. Carson Director | Bought | 4,115 | $2.46 | 10K | 16% | Form 4 |
| Feb 18, 2025 | Jamie Dananberg Chief Medical Officer | SoldNo plan | 5,521 | $2.96 | 16K | 14% | Form 4 |
| Feb 18, 2025 | Dean Richard Artis EVP & Chief Scientific Officer | SoldNo plan | 5,515 | $2.97 | 16K | 6.2% | Form 4 |
| Feb 18, 2025 | Ted Yednock EVP & Chief Innovation Officer | SoldNo plan | 8,345 | $2.91 | 24K | 12% | Form 4 |
| Feb 18, 2025 | Michael Overdorf EVP & Chief Business Officer | SoldNo plan | 6,618 | $2.95 | 20K | 7.1% | Form 4 |
| Feb 18, 2025 | Jennifer Lew EVP & Chief Financial Officer | SoldNo plan | 6,912 | $2.92 | 20K | 8.2% | Form 4 |
| Feb 13, 2025 | Douglas Love President and CEO | SoldNo plan | 5,021 | $2.95 | 15K | 1.4% | Form 4 |
| Feb 13, 2025 | Jennifer Lew EVP & Chief Financial Officer | SoldNo plan | 1,786 | $2.98 | 5K | 2.1% | Form 4 |
| Feb 13, 2025 | Ted Yednock EVP & Chief Innovation Officer | SoldNo plan | 1,783 | $2.99 | 5K | 2.5% | Form 4 |
| Feb 13, 2025 | Michael Overdorf EVP & Chief Business Officer | SoldNo plan | 1,425 | $2.99 | 4K | 1.5% | Form 4 |
| Dec 2, 2024 | William H. Carson Director | Bought | 3,200 | $5.33 | 17K | 14% | Form 4 |
- Nov 19William H. CarsonDirector · bought 34,000 at $3.58122K43% of stake
- Sep 24Douglas LovePresident and CEO · bought 26,065 at $3.83100K7.2% of stake
- May 28Muneer A SatterDirector · bought 613,497 at $5.41$3.32M6.3% of stake
- May 11William H. CarsonDirector · bought 8,000 at $5.7846K11% of stake
- Apr 10William H. CarsonDirector · bought 8,000 at $6.2050K13% of stake
- Mar 10William H. CarsonDirector · bought 8,000 at $5.6745K15% of stake
- Mar 2No planDean Richard ArtisEVP & Chief Scientific Officer · sold 5,894 at $5.4332K3.2% of stake
- Mar 2No planTed YednockEVP & Chief Innovation Officer · sold 5,566 at $5.4230K3.5% of stake
- Mar 2No planMichael OverdorfEVP & Chief Business Officer · sold 4,339 at $5.4224K2.3% of stake
- Mar 2No planJamie DananbergChief Medical Officer · sold 5,820 at $5.4332K4.5% of stake
- Mar 2No planJennifer LewEVP & Chief Financial Officer · sold 5,565 at $5.4230K3.2% of stake
- Feb 18No planDean Richard ArtisEVP & Chief Scientific Officer · sold 5,290 at $5.1027K4.1% of stake
- Feb 18No planTed YednockEVP & Chief Innovation Officer · sold 7,857 at $5.1140K7.5% of stake
- Feb 18No planMichael OverdorfEVP & Chief Business Officer · sold 6,225 at $5.1032K4.8% of stake
- Feb 18No planJamie DananbergChief Medical Officer · sold 5,290 at $5.1027K6.7% of stake
- Feb 18No planJennifer LewEVP & Chief Financial Officer · sold 7,851 at $5.1140K6.5% of stake
- Dec 30, 2025William H. CarsonDirector · bought 4,115 at $5.0221K8.2% of stake
- Dec 1, 2025William H. CarsonDirector · bought 4,115 at $4.4718K8.9% of stake
- Dec 1, 2025Jung ChoiDirector · bought 33,000 at $4.19138KNew position
- Nov 20, 2025 – Nov 21, 2025Muneer A SatterDirector · bought 822,613 at avg $4.38$3.6M9.2% of stake
- Nov 17, 2025 – Nov 19, 2025Muneer A SatterDirector · bought 1,500,000 at avg $3.37$5.05M20% of stake
- Oct 30, 2025William H. CarsonDirector · bought 4,115 at $3.1713K9.8% of stake
- Sep 30, 2025William H. CarsonDirector · bought 4,115 at $3.0513K11% of stake
- Sep 2, 2025William H. CarsonDirector · bought 4,115 at $2.099K12% of stake
- Jul 30, 2025William H. CarsonDirector · bought 4,115 at $2.4310K14% of stake
- Jul 14, 2025No planTed YednockEVP & Chief Innovation Officer · sold 1,116 at $2.583K1.1% of stake
- Jul 14, 2025No planJennifer LewEVP & Chief Financial Officer · sold 1,117 at $2.583K0.9% of stake
- Jul 14, 2025No planMichael OverdorfEVP & Chief Business Officer · sold 853 at $2.612K0.6% of stake
- Jun 30, 2025William H. CarsonDirector · bought 4,115 at $2.4610K16% of stake
- Feb 18, 2025No planJamie DananbergChief Medical Officer · sold 5,521 at $2.9616K14% of stake
- Feb 18, 2025No planDean Richard ArtisEVP & Chief Scientific Officer · sold 5,515 at $2.9716K6.2% of stake
- Feb 18, 2025No planTed YednockEVP & Chief Innovation Officer · sold 8,345 at $2.9124K12% of stake
- Feb 18, 2025No planMichael OverdorfEVP & Chief Business Officer · sold 6,618 at $2.9520K7.1% of stake
- Feb 18, 2025No planJennifer LewEVP & Chief Financial Officer · sold 6,912 at $2.9220K8.2% of stake
- Feb 13, 2025No planDouglas LovePresident and CEO · sold 5,021 at $2.9515K1.4% of stake
- Feb 13, 2025No planJennifer LewEVP & Chief Financial Officer · sold 1,786 at $2.985K2.1% of stake
- Feb 13, 2025No planTed YednockEVP & Chief Innovation Officer · sold 1,783 at $2.995K2.5% of stake
- Feb 13, 2025No planMichael OverdorfEVP & Chief Business Officer · sold 1,425 at $2.994K1.5% of stake
- Dec 2, 2024William H. CarsonDirector · bought 3,200 at $5.3317K14% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with ANNX
Held by ETFs
ANNX is in 28 US ETFs. The largest of them, with ANNX's weight in each:
Spot a number that looks wrong? Check it in ANNX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ANNX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.